Full Press Release Details
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026. “We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology,” said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. “We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the signifi